consistently the best people I’ve met since moving to sf have been the ones who also grew up in the middl of nowhere and managed to leave their hometowns

Index freshness is something I and many others at Google have worked on for many years.

We’ve announced a new pilot program that can slash the FDA’s drug review time from 10 to 12 months to just 1-2 months. The new Commissioner National Priority Voucher program is designed to bring more cures and meaningful treatments to the American public. For more than a

Key to research success: ambition in vision, but pragmatism in execution. You must be guided by a long-term, ambitious goal that addresses a fundamental problem, rather than chasing incremental gains on established benchmarks. Yet, your progress should be grounded by tractable

1/🚨WOW! Here is Dr. Marty Makary’s full “Make American Biotech Accelerate” - #MABA op-ed from today’s Washington Post. In his “MABA op-ed” Dr. Makary - the FDA Commissioner, formally introduced his new “Commissioner National Priority Voucher” program that aims to slash the FDA’s

Excited to announce our license of Gusacitinib to Sanofi for upwards of €545M in upfront and milestones in addition to royalties in the low to mid-teen based on future sales.

this summer NewLimit, we built our first prototype medicine that restores multiple youthful functions in old hepatocytes. rejuvenating old cells across multiple dimensions seems more possible today than just months ago. recent highlights - +3 TF sets that restore function in

Today we're announcing that Eventual has raised $30M in Seed and Series A funding from CRV and Felicis as well as Y Combinator, M12 - Microsoft's Venture Fund and Citi and others. The AI era needs data infrastructure built for AI, not retrofitted. 🧵

We CRV are incredibly excited to announce our investments in two companies paving the way for the multimodal data stack! We are thrilled to partner with Daft and LanceDB as they revolutionize the way that multimodal data is processed and stored in the AI era.

Move to SF! ✌️

Another gene therapy death BTW. This one out of China reported in NEJM. Safety is biggest issue with gene therapies and all new therapeutic modalities. Would patients tolerate this many deaths with small molecules? Antibodies? RNAi? So far looks like IV AAV gene therapies are

We've grown a lot despite historically grim market conditions in biotech and the reason for this is interesting. Adoption of new data generation methods across industry still fragmented so we now work directly with the companies that build + sell them.

Interesting options to build the ScaleAI of bio: 1) Given a set of tier 1 and tier 2 data for a molecule and a set of follow-up experimental options, decide what to do next - explain your reasoning. (This data can be curated from patents/literature, generated in lab at scale, or

Data is the oil of modern biotech. New tools allow us to model living systems too complex for unaided human cognition. Latch is releasing a new capabilities in data curation + delivery: - 30M observational cell atlas across 150 diseases, 200 tissues, 27 technologies - a

Learn how to find cracked people from Iowa, Ohio, Pittsburgh, Atlanta, North Carolina, Wisconsin/Minnesota, and Nebraska. They are so good and waiting for an opportunity to unleash limitless potential.

We’re excited to introduce Chai-2, a major breakthrough in molecular design. Chai-2 enables zero-shot antibody discovery in a 24-well plate, exceeding previous SOTA by >100x. Thread👇

Dimension portco Monte Rosa Therapeutics, Inc casually on the cover of Science 🚀

More oil, more gas, more solar, more nuclear, more geothermal, more all of the things. No subsidies. Let market determine which energy source works best for them. Allow companies to build ALL the options and electricity prices will go down.

San Francisco just got a proposal for the tallest tower on the West Coast. And this is not just about one building. This plan would transform a vacant city block into a dynamic mix of housing, office space, retail, and public space by developing the former PG&E and Matson

The NIH announcement of no “animal model only” grants is arguably a bigger deal than the pending 40% budget cut. The question is what it really means. e.g., mice + AI = “not pure animal model” grant etc. Jay Bhattacharya, MD, PhD NIH HHS.gov please clarify. I’m getting Qs galore.